A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers

• Status: Completed
• Trial end date: 2015-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

To determine whether the combination of MM-121 plus paclitaxel is more effective than paclitaxel alone

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merrimack Pharmaceuticals
• Collaborator: Sanofi
• Treatments: Albumin-Bound Paclitaxel; Paclitaxel

Criteria

Inclusion Criteria:

• Locally advanced/metastatic or recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer

• Received at least one prior platinum based chemotherapy regimen

• Platinum-resistant or refractory

• Eligible for weekly paclitaxel

• Adequate liver and kidney function

• 18 years of age or above

Exclusion Criteria:

• Evidence of any other active malignancy

• History of severe allergic reactions to paclitaxel or other drugs formulated in Cremophor®EL